ArcticZymes turnaround & firing on all cylinders
The Turnaround of ArcticZymes is now definitive. For the second quarter we see impressive growth and the company is firing on all cylinders. Opex (cost) going down while earnings as well as profits surge.
ArcticZymes Q2 report
Sales of NOK 44.3 million (16.9) +262%
EBITDA of NOK 27.2 million (-0.5)
Cash-flow for the Q2 was NOK 20.4 million (-6.8)
Cash at hand NOK 56,1 million
Gross margin 90%
CEO Jethro Holter says in the earnings call: "The main growth driver has been sales of the Salt Active Nuclease (SAN) products to the therapeutics segment. The SAN products continue to attract new customers who are developing gene therapies and vaccines. Furthermore, our well-established customers are regularly submitting substantially larger orders as they advance their development programs."
Full report
pdf here: newsweb.oslobors.no/obsvc/attachment.obsvc?messageId=511588&attachmentId=204090&obsvc.item=1
text: newsweb.oslobors.no/message/511588
ArcticZymes Q2 report
Sales of NOK 44.3 million (16.9) +262%
EBITDA of NOK 27.2 million (-0.5)
Cash-flow for the Q2 was NOK 20.4 million (-6.8)
Cash at hand NOK 56,1 million
Gross margin 90%
CEO Jethro Holter says in the earnings call: "The main growth driver has been sales of the Salt Active Nuclease (SAN) products to the therapeutics segment. The SAN products continue to attract new customers who are developing gene therapies and vaccines. Furthermore, our well-established customers are regularly submitting substantially larger orders as they advance their development programs."
Full report
pdf here: newsweb.oslobors.no/obsvc/attachment.obsvc?messageId=511588&attachmentId=204090&obsvc.item=1
text: newsweb.oslobors.no/message/511588
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.